HCPCS Level II code J9063 denotes the injectable oncology agent mirvetuximab soravtansine-gynx, billed per 1 mg. As a specialized antibody-drug conjugate used in cancer care, this code captures high-cost drug administration that affects infusion workflows, payer coverage policies, and hospital outpatient billing. Nationally, accurate use of J9063 is important for claims processing, reimbursement tracking, and clinical cost management for oncology practices and health systems.

Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, typical site-of-service billing considerations, and common clinical contexts for use. Readers will find benchmarks for utilization and reimbursement structures, summaries of relevant policy updates affecting drug coding and billing, and clinical context describing how the product is administered and coded on the claim. The analysis clarifies where data is available and notes areas with limited publicly available information.

This summary provides clinicians, coders, and revenue leaders a concise reference for the code’s clinical purpose, expected billing setting, and the payer landscape relevant to mirvetuximab soravtansine-gynx.